益豐藥房(603939.SH):控股股東及一致行動人大宗交易減持1.76%股份
格隆匯9月21日丨益豐藥房(603939.SH)公佈,公司於2020年9月21日,公司收到控股股東濟康及其一致行動人益之豐、益仁堂的通知函,因資金需求原因,濟康、益之豐、益仁堂合計通過大宗交易減持公司股份935.2778萬股,佔公司總股本的1.76%。
濟康、益之豐與益仁堂已於2018年12月5日至2020年9月21日通過大宗交易累計主動減持公司股份2062.6778萬股,佔公司總股本的4.76%;另外,公司於2016年至今,因增發股份,導致濟康、益之豐、益仁堂及其一致行動人高毅股份被動稀釋比例累計為8.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.